Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a once-weekly injection. It’s administered with a tiny needle that punctures ...

Downside to dropping pounds? The new pill form of popular GLP-1 drugs contains a compound that could cause troubling side ...

Novo Nordisk announced today that Health Canada has approved Ozempic® (semaglutide injection) to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a once-weekly injection. It’s administered with a tiny needle that punctures ...

Zydus Lifesciences will roll out generic semaglutide injections in India post-patent expiry, using a reusable single-pen ...

DCGI had earlier provided its approval for manufacturing and marketing Semaglutide injection for the treatment of Type 2 ...

Semaglutide's patent expiry in India could sharply reduce the cost of popular weight-loss and diabetes injections.

Feb 25 - Zydus Lifesciences will launch generic versions of semaglutide injections for ‌obesity and diabetes in India after ‌patent expiry of the Ozempic active ingredient in ​late March, it said on ...

Zydus to launch Semaglutide Injection in India, featuring a unique reusable pen for improved diabetes and obesity management.

Orforglipron, a novel oral nonpeptide GLP-1 receptor agonist (RA), led to a greater reduction in A1c and more significant weight loss compared to oral semaglutide in patients with type 2 diabetes (T2D ...

Ozempic (R) was approved by Health Canada in 2018. Ozempic (R) is indicated for the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control.